BiotechTube

SHR7280 tablets + SHR7280 dry suspension

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Endometriosis, Uterine Fibroids, Male Hormone-sensitive Prostate Cancer, Assisted Reproduction

Conditions

Endometriosis, Uterine Fibroids, Male Hormone-sensitive Prostate Cancer, Assisted Reproduction

Trial Timeline

May 23, 2023 → Oct 20, 2023

NCT ID
NCT05868057

About SHR7280 tablets + SHR7280 dry suspension

SHR7280 tablets + SHR7280 dry suspension is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Endometriosis, Uterine Fibroids, Male Hormone-sensitive Prostate Cancer, Assisted Reproduction. The current trial status is completed. This product is registered under clinical trial identifier NCT05868057. Target conditions include Endometriosis, Uterine Fibroids, Male Hormone-sensitive Prostate Cancer, Assisted Reproduction.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05868057Phase 1Completed

Competing Products

20 competing products in Endometriosis, Uterine Fibroids, Male Hormone-sensitive Prostate Cancer, Assisted Reproduction

See all competitors
ProductCompanyStageHype Score
ASP1707 + Placebo + Leuprorelin acetateAstellas PharmaPhase 2
52
40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetateSumitomo PharmaPhase 3
77
SHR7280 TabletsJiangsu Hengrui MedicinePhase 1
33
SHR7280 + Placebo oral tabletJiangsu Hengrui MedicinePhase 1/2
41
SHR7280 Tablet + SHR7280 Placebo TabletJiangsu Hengrui MedicinePhase 1
33
Placebo + ElagolixAbbViePhase 2
52
Elagolix + Placebo + Combined Oral ContraceptiveAbbViePhase 3
77
Estradiol/Norethindrone Acetate + Placebo for Elagolix + Elagolix + Placebo for E2/NETAAbbViePhase 3
77
ElagolixAbbViePhase 3
77
elagolix + estradiol/norethindrone acetate (E2/NETA)AbbViePhase 3
77
Elagolix + placeboAbbViePhase 2
52
ElagolixAbbViePhase 3
77
Elagolix + Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) + Placebo to Elagolix + Placebo to DMPA-SCAbbViePhase 2
52
elagolixAbbViePhase 3
77
ElagolixAbbViePhase 3
77
Leuprorelin Acetate Depot + Elagolix + Placebo to Elagolix + Placebo to Leuprorelin AcetateAbbViePhase 2
52
Gefapixant + Placebo + NaproxenMerckPhase 2
52
BGS649 + PlaceboNovartisPhase 2
52
Active treatment with a high dose of BGS649 + Active treatment with a low dose of BGS649 + Placebo treatment to blind studyNovartisPhase 2
52
LetrozoleNovartisPhase 2
52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85